1-2 of 2
Keywords: Bacille Calmette-Guérin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study

Free
Subject Area:
High Impact Articles in Further Areas , Further Areas
Tarun Pareek, Kalpesh Parmar, Aditya Prakash Sharma, Santosh Kumar
Journal: Urologia Internationalis
Urol Int (2022) 106 (8): 784–790.
https://doi.org/10.1159/000524098
Published Online: 23 August 2022
...Tarun Pareek; Kalpesh Parmar; Aditya Prakash Sharma; Santosh Kumar Purpose: Bacille Calmette-Guerin (BCG) is considered the most effective agent for non-muscle invasive bladder cancer (NMIBC). However, due to BCG-related toxicity, multiple studies have suggested the role of newer chemotherapeutic...
View article titled, Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study
Open the PDF for Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study in another window
Journal Articles

Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study

Available to Purchase
Subject Area:
Further Areas
Mauro Gacci, Riccardo Bartoletti, Tommaso Cai, Stefano Nerozzi, Novello Pinzi, Fabrizio Repetti, Fabrizio Viggiani, Paolo Ghezzi, Gabriella Nesi, Marco Carini
Journal: Urologia Internationalis
Urol Int (2006) 76 (2): 106–111.
https://doi.org/10.1159/000090870
Published Online: 24 February 2006
... in a very selected population of bacille Calmette-Guérin (BCG)-resistant T1G3 patients. Methods: 9 recurrent BCG-refractory pT1G3 patients, unsuitable for radical treatment, were treated with GEM, and compared with 10 pT1G3 patients previously treated with at least two courses of transurethral resection...
View article titled, Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study
Open the PDF for Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study in another window